Nearly 40% of alopecia areata cases begin before age 20, yet until now the systemic treatment options for adolescents were far narrower than for adults. The FDA’s approval of baricitinib (Olumiant) for patients 12 and older with severe AA changes that calculus with concrete evidence behind it: in BRAVE-AA-PEDS, 42% of adolescents on the 4 mg dose reached 80% or more scalp hair coverage by week 36, against 5% on placebo. That 37-percentage-point gap is the number clinicians will weigh when counseling families.
The trial design matters as much as the result. BRAVE-AA-PEDS enrolled 257 adolescents randomized across all three arms, making it the first and largest Phase 3 study built specifically around pediatric severe AA rather than an adult program with a tacked-on younger cohort. Baseline SALT scores sat at a median of 100, meaning complete scalp hair loss, and participants had lived with the disease for an average of 6.4 years. At the higher dose, 37% also achieved 90% or more scalp coverage at week 36, and patients with substantial eyebrow and eyelash loss at baseline showed improvement in both, extending the response beyond the scalp. The adult BRAVE-AA program reported 38.8% reaching SALT ≤20 on 4 mg in BRAVE-AA1, so the pediatric response at the same dose is numerically comparable, though cross-trial comparisons carry the usual caveats.
The labeled safety profile for adolescents mirrors what was observed in adults, including the boxed warning covering serious infections, malignancy, major adverse cardiovascular events, and thrombosis. That consistency is reassuring for regulatory consistency but also means the risk-benefit conversation with adolescent patients and their parents carries the same complexity it does in adult rheumatology. The recommended starting dose is 2 mg daily, with escalation to 4 mg if the response is inadequate, and a step-down to 2 mg once adequate response on 4 mg is achieved.
The approval builds on Lilly’s 2022 adult label and follows an April 2026 European Commission approval for the same adolescent indication. The metric worth tracking now is how payer coverage for the pediatric label develops: Lilly currently holds formulary positions at three of the largest PBMs for adults with severe AA, and whether that access extends to the new pediatric indication will determine how many of those 12-to-17-year-olds with complete scalp hair loss can actually fill a prescription.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
